Please assess the completion status of the following clinical trial:

Trial Title: A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18 years of age or older~* Patients that are being prescribed REVLIMID in combination with dexamethasone for the treatment of multiple myeloma and that have received at least one prior therapy~* Patient must be willing and able to provide informed consent~* Patients will be informed about the Registry and will have to sign a specific Registry Informed Consent Form~* Be able to ask questions prior to signing the Subject Information and Consent Form~* Be clearly informed that their involvement/participation in the registry is voluntary~* Understand that their medical care will not be altered in any way by their participation in the registry~Exclusion Criteria:~- A Patient who is unwilling or unable to provide informed consent will not be included.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REVLIMID (Type: None): Taiwanese patients treated with REVLIMID

Based on this trial design, predict the completion outcome and termination type (if applicable).